Bio Green Med Solution, INC. (BGMSP) — SEC Filings

Overview

Bio Green Med Solution, INC. (BGMSP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K/A filed on Nov 26, 2025: Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) filed a 10-K/A on November 26, 2025, primarily to incorporate a re-audit report for the full fiscal years 2024 and 2023 by a single independent registered public accounting firm, aiming for future cost efficiencies. The company a

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bearish, 41 neutral, 6 mixed. The dominant filing sentiment for Bio Green Med Solution, INC. is neutral.

Filing Type Overview

Bio Green Med Solution, INC. (BGMSP) has filed 1 10-K/A, 3 10-Q, 35 8-K, 1 8-K/A, 2 DEFA14A, 1 S-1/A, 2 S-1, 2 DEF 14A, 1 10-K, 1 SC 13G, 1 SC 13G/A with the SEC between Nov 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Bio Green Med Solution Narrows Focus, Secures Funding Amid Re-Audit — 10-K/A · Nov 26, 2025 Risk: high
  Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) filed a 10-K/A on November 26, 2025, primarily to incorporate a re-audit report for the f
• BGMSP Pivots to Fire Safety, Reports $5M Deconsolidation Gain — 10-Q · Nov 13, 2025 Risk: high
  Bio Green Med Solution, Inc. (BGMSP) underwent a significant strategic shift in 2025, transitioning from a biopharmaceutical company to a diversified entity foc
• Bio Green Med Solution Files 8-K: Material Agreement, Equity Sales — 8-K · Nov 6, 2025 Risk: medium
  Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc. and XCYTE THERAPIES INC) filed an 8-K on November 5, 2025. The filing indicates the compan
• Bio Green Med Solution, Inc. Files 8-K on Asset Deal — 8-K · Oct 7, 2025 Risk: medium
  Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc. and Xcyte Therapies Inc.) filed an 8-K on October 7, 2025, reporting on the entry into a m
• Bio Green Med Solution, Inc. Files 8-K on Officer/Director Changes — 8-K · Sep 25, 2025 Risk: medium
  Bio Green Med Solution, Inc. filed an 8-K on September 25, 2025, reporting events as of September 19, 2025. The filing pertains to the departure of directors or
• Bio Green Med Solution Files 8-K/A Amendment — 8-K/A · Sep 17, 2025 Risk: medium
  Bio Green Med Solution, Inc. filed an amendment (8-K/A) on September 17, 2025, to a previous report concerning events on September 12, 2025. The filing pertains
• Bio Green Med Solution Faces Delisting Notice — 8-K · Sep 16, 2025 Risk: high
  Bio Green Med Solution, Inc. filed an 8-K on September 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, fo
• Cyclacel Pharmaceuticals Files 8-K on Asset Deal & Charter Changes — 8-K · Sep 12, 2025 Risk: medium
  On September 12, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report indicating a completion of an acquisition or disposition of assets. The filing also no
• Cyclacel Pharmaceuticals Files 8-K on Shareholder Votes & Financials — 8-K · Sep 5, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on September 5, 2025, reporting on matters submitted to a vote of security holders and financial statements. The fil
• Cyclacel Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — 8-K · Sep 4, 2025 Risk: medium
  On September 4, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of
• Cyclacel Pharmaceuticals Reports Material Definitive Agreement — 8-K · Sep 2, 2025 Risk: medium
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on September 2, 2025, reporting a material definitive agreement. The filing does not contain specific details about
• Cyclacel Pharmaceuticals Changes Certifying Accountant — 8-K · Aug 28, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on August 28, 2025, reporting a change in its certifying accountant as of August 22, 2025. The filing also includes
• Cyclacel Pharmaceuticals Files Proxy Materials — DEFA14A · Aug 25, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on August 25, 2025. This filing is related to proxy materials and does not requ
• Cyclacel Narrows Loss Amid Strategic Pivot, Proposed Merger — 10-Q · Aug 14, 2025 Risk: high
  Cyclacel Pharmaceuticals, Inc. reported a net loss of $1.399 million for the six months ended June 30, 2025, a significant improvement from the $6.203 million n
• Cyclacel Pharmaceuticals Files 8-K — 8-K · Aug 13, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on August 13, 2025, reporting financial statements and exhibits as of August 12, 2025. The company, formerly known a
• Cyclacel Amends S-1 for Continuous Offering, Shifts HQ to Malaysia — S-1/A · Jul 31, 2025 Risk: high
  Cyclacel Pharmaceuticals, Inc. filed an S-1/A on July 30, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a strategic move t
• Cyclacel Pharmaceuticals Files 8-K — 8-K · Jul 28, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on July 28, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The comp
• Cyclacel Files S-1 for Continuous Offering, Signals Capital Raise — S-1 · Jul 24, 2025 Risk: high
  Cyclacel Pharmaceuticals, Inc. filed an S-1 registration statement on July 24, 2025, for a proposed public offering of securities on a delayed or continuous bas
• Cyclacel Pharmaceuticals Files 8-K — 8-K · Jul 16, 2025 Risk: low
  On July 15, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibi
• Cyclacel Pharmaceuticals Files 8-K Report — 8-K · Jul 7, 2025 Risk: low
  On July 7, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosure
• Cyclacel Pharmaceuticals Files 8-K with Corporate Updates — 8-K · Jul 2, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on July 2, 2025, reporting amendments to its Articles of Incorporation or Bylaws, a Regulation FD disclosure, and fi
• Cyclacel Pharmaceuticals Files 8-K on June 30, 2025 — 8-K · Jun 30, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on June 30, 2025, reporting on matters submitted to a vote of security holders and including financial statements an
• Cyclacel Pharma Executive Compensation Details Revealed — DEFA14A · Jun 25, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed a DEFA14A on June 25, 2025, detailing executive compensation for the fiscal years ending December 31, 2024, 2023, and 2022.
• Cyclacel Pharmaceuticals Files 8-K with Key Corporate Updates — 8-K · Jun 20, 2025 Risk: medium
  On June 20, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agr
• Cyclacel Pharmaceuticals Changes Address — 8-K · Jun 3, 2025 Risk: low
  On June 3, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's address is now Level 10, Tower 11, Avenue 5, The Horizon
• Cyclacel Pharmaceuticals Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition as of May 14, 2025. The filing detai
• Cyclacel Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Xcyte Therapies Inc., is incorpor
• Cyclacel Pharmaceuticals Files 8-K with Bylaw Amendments — 8-K · May 7, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on May 7, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and fin
• Cyclacel Pharmaceuticals Files 8-K Report — 8-K · May 6, 2025 Risk: low
  On May 6, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures
• Cyclacel Pharmaceuticals Files S-1 for Securities Registration — S-1 · Apr 25, 2025 Risk: medium
  Cyclacel Pharmaceuticals, Inc. filed an S-1 registration statement on April 25, 2025, to register securities under the Securities Act of 1933. The company, form
• Cyclacel Pharmaceuticals Files 8-K — 8-K · Apr 25, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on April 25, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The com
• Cyclacel Pharma Files DEF 14A on Exec Comp & Stock Awards — DEF 14A · Apr 24, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation and stock option awards for the fiscal years ending December
• Cyclacel Pharmaceuticals Changes Principal Executive Offices — 8-K · Apr 21, 2025 Risk: medium
  On April 21, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to Kuala Lumpu
• Cyclacel Pharmaceuticals Files 8-K: Operations, Officers, Financials — 8-K · Apr 2, 2025 Risk: medium
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on April 2, 2025, reporting events as of March 31, 2025. The filing covers results of operations, financial conditio
• Cyclacel Pharmaceuticals Files 2024 10-K, Details Warrant Activity — 10-K · Apr 2, 2025 Risk: medium
  Cyclacel Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as XCYTE THERAPIES INC, is incorporated
• Cyclacel Pharmaceuticals Files 8-K with Key Corporate Updates — 8-K · Mar 24, 2025 Risk: medium
  On March 21, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive ag
• Cyclacel Pharmaceuticals Files 8-K on Key Agreements and Acquisitions — 8-K · Mar 14, 2025 Risk: medium
  On March 10, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement and the completion of an acquisition or disposit
• Cyclacel Pharmaceuticals Files 8-K: Delisting Notice, Control Change — 8-K · Feb 27, 2025 Risk: high
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on February 27, 2025, reporting several material events. These include entering into a material definitive agreement
• Cyclacel Pharmaceuticals Files 8-K: Material Agreement & Exhibits — 8-K · Feb 24, 2025 Risk: medium
  On February 20, 2025, Cyclacel Pharmaceuticals, Inc. entered into a material definitive agreement. The company also filed financial statements and exhibits as p
• Cyclacel Pharmaceuticals Files 8-K on Security Holder Rights — 8-K · Feb 12, 2025 Risk: medium
  On February 6, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its article
• Cyclacel Pharmaceuticals Files 8-K with Key Corporate Updates — 8-K · Feb 6, 2025 Risk: medium
  On February 4, 2025, Cyclacel Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity secu
• Cyclacel Pharmaceuticals Files 8-K: Other Event — 8-K · Feb 5, 2025 Risk: medium
  On January 31, 2025, Cyclacel Pharmaceuticals, Inc. reported an "Other Event" in its Form 8-K filing. The filing does not contain specific details about the nat
• Cyclacel Pharma Files 2025 Proxy Statement — DEF 14A · Jan 21, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on January 21, 2025, for its annual meeting on February 6, 2025. The filing details
• Cyclacel Pharmaceuticals Files 8-K Report — 8-K · Jan 10, 2025 Risk: low
  On January 9, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, incorpor
• Cyclacel Pharmaceuticals 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Jan 6, 2025 Risk: medium
  Cyclacel Pharmaceuticals, Inc. filed an 8-K on January 6, 2025, reporting on several key events. These include entering into a material definitive agreement, un
• Cyclacel Pharmaceuticals Faces Delisting Concerns — 8-K · Dec 12, 2024 Risk: high
  Cyclacel Pharmaceuticals, Inc. has filed an 8-K report on December 12, 2024, indicating a notice of delisting or failure to meet continued listing standards. Th
• Cyclacel Pharmaceuticals Files 8-K: Agreements & Equity Update — 8-K · Nov 15, 2024 Risk: medium
  On November 13, 2024, Cyclacel Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Sec
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Cyclacel Pharmaceuticals to be Acquired by Verastem, Inc. — 8-K · Nov 12, 2024 Risk: medium
  Cyclacel Pharmaceuticals, Inc. announced on November 5, 2024, that it has entered into a definitive agreement to be acquired by Verastem, Inc. The transaction i

Risk Profile

Risk Assessment: Of BGMSP's 48 recent filings, 8 were flagged as high-risk, 21 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bio Green Med Solution, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $81,000
• Net Income: -$2,387,000
• EPS: -$1.31
• Debt-to-Equity: N/A
• Cash Position: $3,838,000
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• David Lazar
• Professor David Glover, PhD
• David E. Lazar
• Datuk Dr. Doris Wong Sing Ee
• Debbie A. Klis

Industry Context

Bio Green Med Solution, Inc. operates in the highly competitive biopharmaceutical industry, specifically focusing on oncology drug development. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include a growing emphasis on targeted therapies and precision medicine, as well as increasing reliance on strategic partnerships and collaborations to share risk and accelerate development.

Top Tags

material-agreement (14) · corporate-action (8) · equity-sale (7) · filing (7) · financials (7) · corporate-governance (6) · acquisition (4) · financial-reporting (4) · Biotechnology (3) · corporate-filing (3)

Key Numbers

• Gross proceeds from securities purchase agreement: $3.1 million — Received from investor David Lazar for Series C and D Convertible Preferred Stock
• Anticipated increase in stockholders' equity: $5.0 million — Resulting from the deconsolidation of Cyclacel Limited
• Common stock split ratio: 1-for-16 — Effective May 7, 2025
• Aggregate market value of common stock held by non-affiliates: $2,523,882 — As of June 30, 2024, based on a closing price of $388.80
• Shares of common stock outstanding: 863,901 — As of March 27, 2025
• PLK1 IC50 for Plogo: 3 nM — Indicates potent and selective target inhibition
• Product Revenue - Fire Safety: $81K — New revenue stream for the nine months ended September 30, 2025, compared to $0 in 2024, reflecting the business pivot.
• Net Loss (9 months): $2.387M — Reduced from $8.160 million in the prior year, indicating some cost control despite the transition.
• Gain on Deconsolidation of Subsidiary: $4.947M — One-time gain from the liquidation of Cyclacel Limited, significantly impacting other income.
• Research and Development Expenses (9 months): $895K — Substantially decreased from $5.775 million in 2024, reflecting the exit from biopharmaceutical R&D.
• Cash and Cash Equivalents: $3.838M — Increased from $3.137 million at December 31, 2024, supported by financing activities.
• Net Cash Provided by Financing Activities: $5.523M — Crucial for liquidity during the business transformation, primarily from issuing common and preferred stock.
• Deemed Dividend on Warrant Exchange: $1.494M — A non-cash charge impacting net loss applicable to common shareholders.
• Common Shares Outstanding: 3,497,537 — As of September 30, 2025, significantly increased from 36,913 at December 31, 2024, due to conversions and acquisitions.
• Net Loss Per Share (Q3): $1.31 — Improved from $43.80 in Q3 2024, partly due to the increased share count from conversions and acquisitions.

Related Companies

CYCC · CYCCP · BGMS · 9318.KL · VERA

Frequently Asked Questions